一分钟看懂
这是一项关于肺癌的III 期研究，登记的药物或干预包括Firmonertinib；EGFR-TKI inhibitor based on investigator's choice，当前状态为招募中。登记地点显示中国北京、厦门、佛山、汕头等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Firmonertinib；EGFR-TKI inhibitor based on investigator's choice · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University People's Hospital · 北京
- Beijing Chest Hospital, Capital Medical University · 北京
- Zhongshan Hospital Xiamen University · 厦门
- The First People's Hospital of Foshan · 佛山
- Cancer Hospital of Shantou University Medical College · 汕头
- The Fourth Hospital of Hebei Medical University · 石家庄
- Harbin Medical University Cancer Hospital · 哈尔滨
- The First Affiliated Hospital of Henan University of Science & Technology · 洛阳
- The First Affiliated Hospital of Henan Medical University · 新乡
- The First Affiliated Hospital of Zhengzhou University · 郑州
- Union Hospital Tongji Medical College Huazhong University Of Science And Technology · 武汉
- Profile of The Third Xiangya Hospital of Central South University · 长沙
- The Affiliated Hospital of Inner Mongolia Medical University · 呼和浩特
- Jiangsu Province Hospital · 南京
- Nanjing Drum Tower Hospital · 南京
- Affiliated Hospital of Nantong University · 南通
- The First Affiliated Hospital of Nanchang University · 南昌
- China shenyang the tenth People's Hospital · 沈阳
- The Affiliated Hospital of Qingdao University · 青岛
- Weifang People's Hospital · 潍坊
- Shanghai Chest Hospital · 上海
- Shanxi Cancer Hospital · 太原
- Sichuan Cancer Hospital · 成都
- Tianjin Chest Hospital · 天津
- Tianjin Medical University Cancer Institute & Hospital · 天津
- Yunnan Cancer Hospital · 昆明
- Zhejiang Cancer Hospital · 杭州
公开的入选条件
- Key Eligibility Criteria:
- * Histologically or cytologically documented, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy.
- * Documented results of the presence of an Epidermal Growth Factor Receptor (EGFR) PACC mutation in tumor tissue or blood from local testing.
- * No prior systemic anticancer therapy regimens received for locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) including prior treatment with any Epidermal Growth Factor Receptor (EGFR)-targeting agents (e.g., previous (EGFR) TKIs, monoclonal a
- * Patients who have received prior neo-adjuvant and/or adjuvant chemotherapy, immunotherapy, or chemo radiotherapy for non-metastatic disease must have experienced a treatment free interval of at least 12 months.
- * Patients with asymptomatic CNS metastases are eligible.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07185997；登记信息更新于 2026-09-01。